Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Drug Deliv. 2020 Dec;27(1):1165-1175. doi: 10.1080/10717544.2020.1801891.
The endometrial injury usually results in intrauterine adhesions (IUAs). However, there is no effective treatment to promote the regeneration of the endometrium currently. The decellularized amnion membrane (AM) is a promising material in human tissue repair and regeneration due to its biocompatibility, biodegradability, as well as the preservation of abundant bioactive components. Here, an innovative drug-delivering system based on human amniotic extracellular matrix (HAECM) scaffolds were developed to facilitate endometrium regeneration. The 17β-estradiol (E) loaded PLGA microspheres (E-MS) were well dispersed in the scaffolds without altering their high porosity. E released from E-MS-HAECM scaffolds showed a decreased initial burst release followed with a sustained release for 21 days, which coincided with the female menstrual cycle. Results of cell proliferation suggested E-MS-HAECM scaffolds had good biocompatibility and provided more biologic guidance of endometrial cell proliferation except for mechanical supports. Additionally, the mRNA expression of growth factors in endometrial cells indicated that HAECM scaffolds could upregulate the expression of EGF and IGF-1 to achieve endometrium regeneration. Therefore, these advantages provide the drug-loaded bioactive scaffolds with new choices for the treatments of IUAs.
子宫内膜损伤通常会导致宫腔粘连(IUAs)。然而,目前尚无有效的治疗方法来促进子宫内膜的再生。脱细胞羊膜(AM)由于其生物相容性、可生物降解性以及丰富的生物活性成分的保留,是一种很有前途的人类组织修复和再生材料。在这里,开发了一种基于人羊膜细胞外基质(HAECM)支架的创新药物输送系统,以促进子宫内膜再生。载有 17β-雌二醇(E)的 PLGA 微球(E-MS)很好地分散在支架中,而不会改变其高孔隙率。E-MS-HAECM 支架中释放的 E 表现出初始突释减少,随后持续释放 21 天,与女性月经周期一致。细胞增殖结果表明,E-MS-HAECM 支架具有良好的生物相容性,除了提供机械支撑外,还能提供更多的子宫内膜细胞增殖的生物学指导。此外,子宫内膜细胞中生长因子的 mRNA 表达表明,HAECM 支架可以上调 EGF 和 IGF-1 的表达,从而实现子宫内膜再生。因此,这些优势为负载药物的生物活性支架治疗 IUAs 提供了新的选择。